Q1 EPS Forecast for Entrada Therapeutics Lowered by Analyst

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Analysts at HC Wainwright lowered their Q1 2025 earnings per share estimates for shares of Entrada Therapeutics in a note issued to investors on Monday, March 31st. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.92) per share for the quarter, down from their prior forecast of ($0.86). HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Entrada Therapeutics' current full-year earnings is $1.12 per share. HC Wainwright also issued estimates for Entrada Therapeutics' Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.06) EPS, Q4 2025 earnings at ($1.12) EPS and FY2025 earnings at ($4.11) EPS.

Entrada Therapeutics Trading Down 5.1 %

Shares of TRDA traded down $0.42 during mid-day trading on Thursday, reaching $7.77. 60,003 shares of the stock traded hands, compared to its average volume of 119,653. The company has a market cap of $292.11 million, a price-to-earnings ratio of 4.88 and a beta of 0.04. Entrada Therapeutics has a 1 year low of $7.42 and a 1 year high of $21.79. The firm has a fifty day moving average price of $11.46 and a 200 day moving average price of $15.17.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, topping analysts' consensus estimates of ($0.66) by $0.69. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The business had revenue of $12.25 million for the quarter, compared to analyst estimates of $11.95 million.

Remove Ads

Institutional Trading of Entrada Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. KLP Kapitalforvaltning AS purchased a new stake in Entrada Therapeutics in the fourth quarter valued at approximately $36,000. BNP Paribas Financial Markets purchased a new position in Entrada Therapeutics in the fourth quarter worth $57,000. Virtus ETF Advisers LLC bought a new position in Entrada Therapeutics in the fourth quarter valued at $68,000. AlphaQuest LLC bought a new stake in Entrada Therapeutics during the fourth quarter worth about $70,000. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Entrada Therapeutics by 53,455.6% in the 4th quarter. Russell Investments Group Ltd. now owns 4,820 shares of the company's stock worth $83,000 after purchasing an additional 4,811 shares in the last quarter. Hedge funds and other institutional investors own 86.39% of the company's stock.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.